Kinetics and prediction of <scp>HB</scp>sAg loss during therapy with analogues in patients affected by chronic hepatitis B <scp>HB</scp>eAg negative and genotype D

Boglione, Lucio; D’Avolio, Antonio; Castaldo, Giuseppe; Gregori, Gabriella; Burdino, Elisa; Baietto, Lorena; Cusato, Jessica; Ghisetti, Valeria; Rosa, Francesco Giuseppe De; Perri, Giovanni Di

doi:10.1111/liv.12091

Cited by 38 publications

(34 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are not surprising because they are similar to those reported by Boglione et al [8], who showed that ADV had a better serological response than virological response. The potency of LAM on HBsAg reduction was also demonstrated by the study of Seto et al [19], who showed a similar median HBsAg decline rate (0.10 log 10 IU/mL/year) during a 10-year treatment with LAM in patients who had responded to LAM favorably.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B

Wang

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

Background & AimsAbout 350–400 million people are infected with hepatitis B virus (HBV) chronically and 1 million people die of hepatitis B virus (HBV)-related liver diseases. Nucleos(t)ide analogues (NAs) have been used for the treatment against HBV. However, few studies have investigated the long-term effects of different nucleos(t)ide analogues on levels of hepatitis B surface antigen (HBsAg) in patients with chronic hepatitis B (CHB). The aims of this study were to measure the magnitude of HBsAg reduction by long-term monotherapy with adefovir dipivoxil (ADV) and entecavir (ETV), to compare HBsAg reduction between the two drugs of different potency and to predict the expected time needed to achieve HBsAg loss.MethodsWe retrospectively evaluated the kinetics of HBsAg in 67 patients with CHB who all exhibited persistent viral suppression. These patients were treated with ADV or ETV for at least 6 years. HBV genotype was determined at baseline. Liver biochemistry, HBV serological markers, serum HBV DNA and HBsAg titers were determined at baseline, half year and yearly from year 1 to 6.ResultsSerum HBsAg titers after treatment with ADV or ETV were significantly lower than the baseline titers (P<0.05). HBsAg reduction rate of patients treated with ETV (0.11 log10 IU/mL/ year) was higher than that treated with ADV (0.10 log10 IU/mL/year), and the calculated expected time to HBsAg loss for patients treated with ETV (approximate 24.99 years) was shorter than that with ADV (approximate 30.33 years), but there was no statistically significant difference between two groups (P>0.05).ConclusionSerum HBsAg titers gradually decreased during long-term treatment with either ADV or ETV. It appears that the potency of ADV on HBsAg reduction is close to that of ETV, as long as patients have achieved persistent viral suppression.

show abstract

Section: Discussionsupporting

confidence: 91%

“…HBsAg kinetics and prediction of HBsAg loss were demonstrated only during the short-term treatment with individual NAs [8], [9]. However, whether ETV or TDF is more potent toward HBsAg reduction than LAM or ADV remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B

Wang

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…However, the use of PEG-IFN is limited in the hepatitis e antigen (HBeAg)-negative patients for the low rate of virological response and the sideeffects associated with the subcutaneous administration (Zoulim and Perrillo, 2008). Therefore, NAs were the most used treatments in HBeAg-negative patients, but the HBsAg decrease is very poor (Boglione et al, 2013;Chevaliez et al, 2013;Wong et al, 2013) and the HBsAg loss is difficult to achieve.The PEG-IFN therapy could be optimized by selection of patients with best chance of response using baseline predictive factors (Krishnamoorthy and Mutimer, 2015), while host genetic factors as interleukin (IL)28B were analyzed in some studies but without reliable results (Boglione et al, 2014b;Galmozzi et al, 2014;Lampertico et al, 2013). Other promising predictive marker of HBsAg loss seems to be the serum level of interferon-inducible protein 10 (IP10), but has been studied only during NAs therapy .…”

mentioning

confidence: 99%

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon

et al. 2016

Self Cite

View full text Add to dashboard Cite

“…The currently available data would suggest otherwise: HBsAg seroclearance is considered a rare event during NA therapy; this event is observed in only 0.5-1% of all treated patients per year. The rate of decline of serum HBsAg levels is such that, according to mathematical models, a complete elimination could theoretically be achieved in a time frame of 20-30 years [18,19]. This effect could be expected for both HBeAg-positive and HBeAg-negative CHB.…”

Section: Current Hbv Therapiesmentioning

confidence: 94%

Chronic hepatitis B: Are we close to a cure?

Loggi

Vitale

Conti

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

Approximately 300 million people worldwide are persistently infected with the hepatitis B virus and are at risk of developing hepatocellular carcinoma and liver cirrhosis, which can progress to end-stage liver disease. Despite the effectiveness of the current vaccination policy, the prevalence of the disease remains high, and the burden for health services is considerable. The currently available antiviral strategies are either poorly effective or only effective for non-curative suppression of viral replication. Recent efforts have been focused on improving the cure rate for chronic hepatitis B and developing strategies to eliminate infected cells. Several approaches are under evaluation, and these include targeting the virus at different stages of its life cycle and boosting the antiviral immune response. This article reviews these latest approaches and comments on their feasibility and potential translation into clinical applications.

show abstract

Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D

Abstract: HBeAg negative patients infected by HBV genotype D should be treated with more potent NAs such as entecavir or tenofovir to obtain a significant qHBsAg decrease, but the achievement of HBsAg loss seems to require almost two decades of therapy.

Cited by 38 publications

References 17 publications

Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B

Kinetics and Prediction of HBsAg Loss during Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B

Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon

Chronic hepatitis B: Are we close to a cure?

Contact Info

Product

Resources

About